Sean E. Bland, JD; Frank J. Palella, MD; and Carl Schmid explore organizational opportunities to improve access to HIV PrEP therapy and population health management strategies to improve PrEP uptake.
From evidence to implementation: Clarifications around USPSTF recommendations for HIV pre-exposure prophylaxis (PrEP) – Episode 14: COVID-19’s effect on access to HIV PrEP therapy
Carl Schmid discusses how the COVID-19 pandemic has amplified health care disparities and accessing HIV PrEP, and Frank J. Palella, MD, comments on the role of telehealth in improving access to PrEP.
From evidence to implementation: Clarifications around USPSTF recommendations for HIV pre-exposure prophylaxis (PrEP) – Episode 12: Unmet needs for USPSTF guidelines for HIV PrEP
Ryan Bitton, PharmD, MBA; Sean E. Bland, JD; Frank J. Palella, MD; and Carl Schmid comment on challenges in the implementation of USPSTF guidelines for HIV PrEP as well as existing unknowns with the guidance.
Patient Community Perspective
Details the harmful impacts copay accumulators have on drug adherence and patients costs, federal and state actions taken to date to ensure copay assistance counts, and advocacy opportunities at the federal and state levels patient groups can engage in relative to copay accumulators.
From evidence to implementation: Clarifications around USPSTF recommendations for HIV pre-exposure prophylaxis (PrEP) – Episode 9: USPSTF guidelines for HIV PrEP: Coverage for drugs vs ancillary services
Carl Schmid and Frank J. Palella, MD, discuss how coverage differs for medications vs ancillary service costs for HIV PrEP based on USPSTF guidelines.